CD82 and acute myeloid leukemia: Mice were treated 6 weeks after transplantation of AML cells with either AraC (n = 8, 500 mg/kg, on days 0 and 1) and/or CD82 mAb (n = 8, 1 μg, twice a day, on days 0 and 1) (Fig.2A); control mice received isotype control IgG (n = 8, 1 μg, twice a day, on days 0 and 1).